Functional Characterization of CYP2B6 Allelic Variants in Demethylation of Antimalarial Artemether
Authors:
- Yuka MuroiYMYuka Muroi
- Yuichiro TamakiYTYuichiro Tamaki
- Daisuke SaigusaDSDaisuke Saigusa
- Naoto SuzukiNSNaoto Suzuki
- Yoshihisa TomiokaYTYoshihisa Tomioka
- Yoichi MatsubaraYMYoichi Matsubara
- Akifumi OdaAOAkifumi Oda
- Noriyasu HirasawaNHNoriyasu Hirasawa
- Masahiro HiratsukaMasahiro Hiratsuka
- 1 October 2011
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (10) , 1860-1865
Abstract
Artemether (AM) is one of the most effective antimalarial drugs. The elimination half-life of AM is very short, and it shows large interindividual variability in pharmacokinetic parameters. The aim of this study was to identify cytochrome P450 (P450) isozymes responsible for the demethylation of AM and to evaluate functional differences between 26 CYP2B6 allelic variants in vitro. Of 14 recombinant P450s examined in this study, CYP2B6 and CYP3A4 were primarily responsible for production of the desmethyl metabolite dihydroartemisinin. The intrinsic clearance (Vmax/Km) of CYP2B6 was 6-fold higher than that of CYP3A4. AM demethylation activity was correlated with CYP2B6 protein levels (P = 0.004); however, it was not correlated with CYP3A4 protein levels (P = 0.27) in human liver microsomes. Wild-type CYP2B6.1 and 25 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.21 and CYP2B6.23-CYP2B6.27) were heterologously expressed in COS-7 cells. In vitro analysis revealed no enzymatic activity in 5 variants (CYP2B6.8, CYP2B6.12, CYP2B6.18, CYP2B6.21, and CYP2B6.24), lower activity in 7 variants (CYP2B6.10, CYP2B6.11, CYP2B6.14, CYP2B6.15, CYP2B6.16, CYP2B6.20, and CYP2B6.27), and higher activity in 4 variants (CYP2B6.2, CYP2B6.4, CYP2B6.6, and CYP2B6.19), compared with that of wild-type CYP2B6.1. In kinetic analysis, 3 variants (CYP2B6.2, CYP2B6.4, and CYP2B6.6) exhibited significantly higher Vmax, and 3 variants (CYP2B6.14, CYP2B6.20 and CYP2B6.27) exhibited significantly lower Vmax compared with that of CYP2B6.1. This functional analysis of CYP2B6 variants could provide useful information for individualization of antimalarial drug therapy.Keywords
This publication has 36 references indexed in Scilit:
- Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrineMalaria Journal, 2010
- Crystal Structure of a Cytochrome P450 2B6 Genetic Variant in Complex with the Inhibitor 4-(4-Chlorophenyl)imidazole at 2.0-Å ResolutionMolecular Pharmacology, 2010
- Haplotype structure and allele frequencies ofCYP2B6in Spaniards and Central AmericansFundamental & Clinical Pharmacology, 2010
- Pharmacokinetics of Artemether-Lumefantrine and Artesunate-Amodiaquine in Children in Kampala, UgandaAntimicrobial Agents and Chemotherapy, 2010
- Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2009
- Artemisinin–a possible CYP2B6 probe substrate?Biopharmaceutics & Drug Disposition, 2009
- COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMSDrug Metabolism and Disposition, 2003
- Pharmacokinetics of Artemisinin-Type CompoundsClinical Pharmacokinetics, 2000
- Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers1997
- The development and spread of drug-resistant malariaParasitology Today, 1991